Aging Populations And Self-Administration Will Transform MS Care

Key Takeaways

• Accelerated adoption of BRIUMVI and its subcutaneous formulation could rapidly boost market share, revenues, and persistency due to payer and consumer preference trends.
  
• Strong clinical pipeline, brand momentum, and demographic tailwinds position the company for superior long-term growth and margin expansion compared to competitors.
  
• Heavy dependence on a single product combined with pricing pressure, regulatory hurdles, and rising competition threatens revenue growth and long-term profitability.

Catalysts

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

• While analyst consensus recognizes strong domestic and international BRIUMVI launch momentum, the current market penetration of roughly one-third of anti-CD20 IV new patients significantly understates the potential for rapid majority market share, as BRIUMVI's convenience, superior safety profile, and expanding academic and VA presence could accelerate adoption towards becoming the dominant class leader well before its competitors pivot or respond, materially raising revenue and market share faster than expected.
  
• The consensus believes that development and potential approval of subcutaneous BRIUMVI could expand the addressable market by tapping into self-administered preferences, but this view fails to fully account for the likely pace and scale of adoption given the trend of payer-driven preferences for at-home administration. Anticipated rapid payer mandates and consumer shifts could cause subcutaneous BRIUMVI to capture the majority of the 35-40% market segment extremely quickly, driving a step-change in total revenues and persistency.
  
• Sustained growth in the incidence of chronic illnesses, including multiple sclerosis and related B-cell disorders, driven by global demographic changes, positions TG Therapeutics to not just maintain but significantly expand its core addressable market, supporting durable long-term revenue and earnings acceleration.
  
• Massive first-mover advantages in patient and provider engagement, including successful execution of broad-based patient awareness campaigns, high provider and patient satisfaction ratings, and proven brand preference, create a flywheel effect that both compresses customer acquisition costs and meaningfully enhances operational leverage, translating into superior net margin expansion over time compared to sector peers.
  
• The company's robust clinical pipeline, with advanced development not just in multiple sclerosis but in cell therapies such as azer-cel for additional autoimmune and B-cell malignancy indications, positions TG to leverage its expertise and infrastructure to unlock multiple significant revenue streams ahead of competitors, substantially increasing long-term earnings potential beyond what analysts currently project.

TG Therapeutics Future Earnings and Revenue Growth

Assumptions

• This narrative explores a more optimistic perspective on TG Therapeutics compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming TG Therapeutics's revenue will grow by 47.3% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 13.3% today to 44.0% in 3 years time.
• The bullish analysts expect earnings to reach $638.5 million (and earnings per share of $3.83) by about August 2028, up from $60.5 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 15.5x on those 2028 earnings, down from 67.0x today. This future PE is greater than the current PE for the US Biotechs industry at 15.4x.
• Analysts expect the number of shares outstanding to grow by 1.7% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

TG Therapeutics Future Earnings Per Share Growth

Risks

• Persistent downward pressure on drug pricing, noted by ongoing exposure to government-mandated discounting such as 340B programs and payer preference for lower-cost at-home therapies, could erode BRIUMVI's selling price and negatively impact revenue growth and net margins over the long term.
  
• Increasing regulatory scrutiny and lengthy clinical trial timelines, particularly for the subcutaneous BRIUMVI formulation and pipeline candidates like the CD19 CAR-T therapy, risk delaying new product launches and add to R&D expenses, which could lead to higher operating costs and delays in expanding the revenue base.
  
• TG Therapeutics' heavy reliance on a single core product, BRIUMVI, for the majority of its revenue leaves the company vulnerable to competitive threats, market share losses to established rivals, or potential clinical setbacks, any of which could lead to top-line revenue declines and missing earnings forecasts.
  
• High post-approval marketing and commercialization expenses, including a ramp-up in multichannel marketing and expansion of the sales force to compete with larger incumbents, continue to put pressure on operating expenses and may limit future improvements in net profitability.
  
• The emergence of next-generation therapies for multiple sclerosis and possible industry consolidation could intensify competitive pressures, create challenges for reimbursement and access, and increase bargaining power for payers, all of which threaten to limit TG Therapeutics' long-term pricing power and revenue potential.

Valuation

• The assumed bullish price target for TG Therapeutics is $53.0, which is the highest price target estimate amongst analysts. This valuation is based on what can be assumed as the expectations of TG Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $53.0, and the most bearish reporting a price target of just $11.0.
• In order for you to agree with the bullish analysts, you'd need to believe that by 2028, revenues will be $1.5 billion, earnings will come to $638.5 million, and it would be trading on a PE ratio of 15.5x, assuming you use a discount rate of 6.8%.
• Given the current share price of $27.77, the bullish analyst price target of $53.0 is 47.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.